These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 10342919

  • 1. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
    Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
    Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD.
    J Clin Oncol; 1997 Feb; 15(2):653-9. PubMed ID: 9053490
    [Abstract] [Full Text] [Related]

  • 5. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
    Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE.
    Cochrane Database Syst Rev; 2014 Feb; (9):CD003256. PubMed ID: 25313415
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA, Forrest A, Northfelt DW, Mamelok R.
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [Abstract] [Full Text] [Related]

  • 7. Liposomal chemotherapies.
    Smart T.
    GMHC Treat Issues; 1995 Mar; 9(7/8):13. PubMed ID: 11362653
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Paclitaxel for treating KS.
    Proj Inf Perspect; 1997 Nov; (23):15. PubMed ID: 11365372
    [Abstract] [Full Text] [Related]

  • 13. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ, Spencer CM.
    Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. DaunoXome offers KS treatment alternative.
    AIDS Alert; 1996 Jun; 11(6):67-8. PubMed ID: 11363544
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    White RM.
    AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
    [No Abstract] [Full Text] [Related]

  • 18. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
    Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH.
    J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
    [Abstract] [Full Text] [Related]

  • 19. Phase I/II trials of alpha-interferon alone or in combination with zidovudine as maintenance therapy following induction chemotherapy in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma.
    Gill PS.
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):53-7. PubMed ID: 1719642
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.